 | |
| Clinical data | |
|---|---|
| Other names | 07-PNET, fosnetupitant chloride hydrochloride |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C31H35F6N4O5P |
| Molar mass | 688.608 g·mol−1 |
Fosnetupitant is a medication used for the treatment of chemotherapy-induced nausea and vomiting. It is a prodrug of netupitant.[1] It is used in combination with palonosetron hydrochloride and formulated as the salt fosnetupitant chloride hydrochloride for intravenous use.[2]
In 2018, the US Food and Drug Administration approved the intravenous formulation of a fixed dose combination of fosnetupitant and palonosetron.[3][4] The combination is also approved for medical use in the European Union[5] and in Canada.[6]
References[edit]
- ^ Aapro M, Jordan K, Scotté F, Celio L, Karthaus M, Roeland E (2022). "Netupitant-palonosetron (NEPA) for Preventing Chemotherapy-induced Nausea and Vomiting: From Clinical Trials to Daily Practice". Current Cancer Drug Targets. 22 (10): 806–824. doi:10.2174/1568009622666220513094352. PMC 9720881. PMID 35570542.
- ^ "Fosnetupitant/Palonosetron (Intravenous Route)". Mayo Clinic. Archived from the original on June 8, 2022. Retrieved June 8, 2022.
- ^ "Fosnetupitant". DrugBank. Archived from the original on December 2, 2021. Retrieved June 8, 2022.
- ^ "Akynzeo- netupitant and palonosetron capsule Akynzeo- fosnetupitant and palonosetron injection". DailyMed. 28 May 2020. Archived from the original on 18 October 2020. Retrieved 18 July 2020.
- ^ "Akynzeo EPAR". European Medicines Agency (EMA). Archived from the original on 19 March 2020. Retrieved 9 June 2022.
- ^ "Akynzeo (netupitant/palonosetron) capsules" (PDF). Product Insert. Elvium Life Sciences. 31 August 2020. Archived (PDF) from the original on 2022-06-10. Retrieved 2022-06-10.
